-
1
-
-
79551614337
-
Role of postmarketing surveillance in contemporary medicine
-
Woodcock J, Behrman RE, Dal Pan GJ. Role of postmarketing surveillance in contemporary medicine. Annu Rev Med 2011; 62: 1-10.
-
(2011)
Annu Rev Med
, vol.62
, pp. 1-10
-
-
Woodcock, J.1
Behrman, R.E.2
Dal Pan, G.J.3
-
2
-
-
31344467254
-
The risk associated with aprotinin in cardiac surgery
-
Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354(4): 353-365.
-
(2006)
N Engl J Med
, vol.354
, Issue.4
, pp. 353-365
-
-
Mangano, D.T.1
Tudor, I.C.2
Dietzel, C.3
-
3
-
-
39549099909
-
The effect of aprotinin on outcome after coronary-artery bypass grafting
-
Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358(8): 784-793.
-
(2008)
N Engl J Med
, vol.358
, Issue.8
, pp. 784-793
-
-
Shaw, A.D.1
Stafford-Smith, M.2
White, W.D.3
-
4
-
-
39549100109
-
Aprotinin during coronary-artery bypass grafting and risk of death
-
Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358(8): 771-783.
-
(2008)
N Engl J Med
, vol.358
, Issue.8
, pp. 771-783
-
-
Schneeweiss, S.1
Seeger, J.D.2
Landon, J.3
Walker, A.M.4
-
5
-
-
0142186283
-
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
-
Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362(9392): 1255-1260.
-
(2003)
Lancet
, vol.362
, Issue.9392
, pp. 1255-1260
-
-
Henke, M.1
Laszig, R.2
Rube, C.3
-
6
-
-
24944454286
-
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study
-
Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23(25): 5960-5972.
-
(2005)
J Clin Oncol
, vol.23
, Issue.25
, pp. 5960-5972
-
-
Leyland-Jones, B.1
Semiglazov, V.2
Pawlicki, M.3
-
7
-
-
84875004391
-
-
FDA. FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp. FDA,
-
FDA. FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp. FDA, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm
-
(2010)
-
-
-
8
-
-
81455159320
-
ADHD drugs and serious cardiovascular events in children and young adults
-
Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365(20): 1896-1904.
-
(2011)
N Engl J Med
, vol.365
, Issue.20
, pp. 1896-1904
-
-
Cooper, W.O.1
Habel, L.A.2
Sox, C.M.3
-
9
-
-
84867136660
-
-
FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults. FDA, 11-1
-
FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults. FDA, 11-1-2011.
-
(2011)
-
-
-
10
-
-
84867123316
-
-
FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events. FDA, 2-21
-
FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events. FDA, 2-21-2007.
-
(2007)
-
-
-
11
-
-
77957952617
-
Regulatory action on rosiglitazone by the U.S. Food and Drug Administration
-
Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010; 363(16): 1489-1491.
-
(2010)
N Engl J Med
, vol.363
, Issue.16
, pp. 1489-1491
-
-
Woodcock, J.1
Sharfstein, J.M.2
Hamburg, M.3
-
12
-
-
84867136659
-
-
FDA significantly restricts access to the diabetes drug Avandia. FDA, 9-23
-
FDA significantly restricts access to the diabetes drug Avandia. FDA, 9-23-2010.
-
(2010)
-
-
-
13
-
-
77954988618
-
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
-
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304(4): 411-418.
-
(2010)
JAMA
, vol.304
, Issue.4
, pp. 411-418
-
-
Graham, D.J.1
Ouellet-Hellstrom, R.2
MaCurdy, T.E.3
-
14
-
-
84855596103
-
Potential Safety Signals and Their Significance
-
Powers A, Cook GE. Potential Safety Signals and Their Significance. Arch Intern Med 2012; 172: 72-73.
-
(2012)
Arch Intern Med
, vol.172
, pp. 72-73
-
-
Powers, A.1
Cook, G.E.2
-
15
-
-
79851472033
-
Developing the Sentinel System--a national resource for evidence development
-
Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System--a national resource for evidence development. N Engl J Med 2011; 364(6): 498-499.
-
(2011)
N Engl J Med
, vol.364
, Issue.6
, pp. 498-499
-
-
Behrman, R.E.1
Benner, J.S.2
Brown, J.S.3
McClellan, M.4
Woodcock, J.5
Platt, R.6
-
16
-
-
84875005828
-
-
FDA. The Sentinel Initiative National Strategy for Monitoring Medical Product Safety. FDA,
-
FDA. The Sentinel Initiative National Strategy for Monitoring Medical Product Safety. FDA, 2008. http://www.fda.gov/downloads/Safety/FDAsSentinelInitiative/UCM124701.pdf
-
(2008)
-
-
-
17
-
-
84875005997
-
-
Drug Safety Information for Healthcare Professionals. FDA,
-
Drug Safety Information for Healthcare Professionals. FDA, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/default.htm
-
(2010)
-
-
|